CA2926874C - Icotinib-containing topical skin pharmaceutical compositions and uses thereof - Google Patents

Icotinib-containing topical skin pharmaceutical compositions and uses thereof Download PDF

Info

Publication number
CA2926874C
CA2926874C CA2926874A CA2926874A CA2926874C CA 2926874 C CA2926874 C CA 2926874C CA 2926874 A CA2926874 A CA 2926874A CA 2926874 A CA2926874 A CA 2926874A CA 2926874 C CA2926874 C CA 2926874C
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
composition according
concentration
icotinib
lcotinib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2926874A
Other languages
English (en)
French (fr)
Other versions
CA2926874A1 (en
Inventor
Yinxiang Wang
Shujun YUAN
Yanping Wang
Shaojing Hu
Yunyan Hu
Original Assignee
Betta Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betta Pharmaceuticals Co Ltd filed Critical Betta Pharmaceuticals Co Ltd
Publication of CA2926874A1 publication Critical patent/CA2926874A1/en
Application granted granted Critical
Publication of CA2926874C publication Critical patent/CA2926874C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2926874A 2013-10-11 2014-10-11 Icotinib-containing topical skin pharmaceutical compositions and uses thereof Expired - Fee Related CA2926874C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2013/085042 2013-10-11
CN2013085042 2013-10-11
PCT/CN2014/088344 WO2015051763A1 (zh) 2013-10-11 2014-10-11 一种含埃克替尼的皮肤外用药物组合物及其应用

Publications (2)

Publication Number Publication Date
CA2926874A1 CA2926874A1 (en) 2015-04-16
CA2926874C true CA2926874C (en) 2018-12-11

Family

ID=52812537

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2926874A Expired - Fee Related CA2926874C (en) 2013-10-11 2014-10-11 Icotinib-containing topical skin pharmaceutical compositions and uses thereof

Country Status (13)

Country Link
US (2) US20160235757A1 (https=)
EP (1) EP3056206A4 (https=)
JP (1) JP6463745B2 (https=)
AU (1) AU2014334222B2 (https=)
BR (1) BR112016007627A2 (https=)
CA (1) CA2926874C (https=)
HK (1) HK1213813A1 (https=)
IL (1) IL245015A0 (https=)
NZ (1) NZ718802A (https=)
RU (1) RU2698796C2 (https=)
SG (1) SG11201602826VA (https=)
TW (1) TWI630921B (https=)
WO (1) WO2015051763A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102270538B1 (ko) * 2013-06-09 2021-06-29 베타 파머수티컬 컴퍼니 리미티드 이코티닙 포스페이트의 신규한 다형체 형태 및 이의 용도
WO2022022434A1 (zh) * 2020-07-27 2022-02-03 杭州和正医药有限公司 含托法替尼药学上可接受的盐的药物组合物、制剂及应用
CN116829152A (zh) * 2021-02-02 2023-09-29 贝达药业股份有限公司 埃克替尼在非小细胞肺癌术后辅助治疗中的应用
CN116492293A (zh) * 2022-01-25 2023-07-28 杭州和正医药有限公司 一种含托法替尼的局部用药的药物组合物、制剂及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0618933A2 (pt) * 2005-11-24 2016-09-13 Basf Se método para produzir uma molécula efetora que se liga à queratina, molécula efetora que se liga à queratina, uso das moléculas efetoras que se ligam à queratina, composto, e, dermocosmético
FR2909284B1 (fr) * 2006-11-30 2012-09-21 Galderma Sa Nouvelles compositions sous forme d'onguent sans vaseline comprenant un derive de vitamine d et eventuellement un anti-inflammatoire steroidien
EP2392576B1 (en) 2008-07-08 2016-02-17 Beta Pharma, Inc. Icotinib hydrochloride, synthesis, crystallographic form, medical combination, and uses thereof
GB201010954D0 (en) * 2010-06-29 2010-08-11 Edko Pazarlama Tanitim Ticaret Compositions
MX2013004296A (es) * 2010-10-21 2013-09-26 Cadila Healthcare Ltd Composiciones farmaceuticas topicas que contienen gotas de tamaño nanometrico para el tratamiento de soriasis.

Also Published As

Publication number Publication date
EP3056206A4 (en) 2017-07-05
SG11201602826VA (en) 2016-05-30
JP6463745B2 (ja) 2019-02-06
IL245015A0 (en) 2016-05-31
WO2015051763A1 (zh) 2015-04-16
AU2014334222B2 (en) 2017-03-09
RU2698796C2 (ru) 2019-08-30
CA2926874A1 (en) 2015-04-16
US20190321369A1 (en) 2019-10-24
AU2014334222A1 (en) 2016-05-05
NZ718802A (en) 2017-09-29
EP3056206A1 (en) 2016-08-17
TW201513894A (zh) 2015-04-16
RU2016118063A (ru) 2017-11-16
BR112016007627A2 (pt) 2017-08-01
JP2016532659A (ja) 2016-10-20
TWI630921B (zh) 2018-08-01
US20160235757A1 (en) 2016-08-18
HK1213813A1 (zh) 2016-07-15

Similar Documents

Publication Publication Date Title
CN1300215A (zh) 皮肤病防治剂
US20190321369A1 (en) Icotinib-containing topical skin pharmaceutical compositions and use thereof
WO2022022434A1 (zh) 含托法替尼药学上可接受的盐的药物组合物、制剂及应用
CN108348560A (zh) 包含水飞蓟素和磺烃基醚环糊精的组合物及其使用方法
EP2854784B1 (en) Method for treating skin inflammatory diseases
EP2954897B1 (en) Skin-moisturising or wrinkle-improving external composition and cosmetic composition
US9572777B2 (en) Topical pharmaceutical composition comprising nanonized silver sulfadiazine
CN105101966A (zh) 一种含埃克替尼的皮肤外用药物组合物及其应用
TW202432180A (zh) 局部藥物組合物、其製備方法及其在醫藥上的用途
WO2019044670A1 (ja) ざ瘡様疾患を治療又は予防するための皮膚外用組成物
KR20160061425A (ko) 이코티닙-함유 국소 피부 약학 조성물 및 이의 용도
JP7690469B2 (ja) ヒアルロン酸産生促進剤およびコラーゲン産生促進剤
RU2197235C1 (ru) Раствор для лечения заболеваний кожи, способ его получения и способ лечения заболеваний кожи
Zhang et al. Co-Assembled Ion-pair Complex Nanoparticles from Tranexamic Acid and Metformin with Enhanced Transdermal Efficacy against UVB-Induced Pigmentation
WO2019173219A1 (en) Compositions and methods for treating pigmentation disorders
CN104829678B (zh) 积雪草酸盐及其制备方法和用途
EP2793897B1 (en) Treatment of seborrhoea
WO2025140381A1 (zh) 一种阿达帕林和氨苯砜的复方组合物及其制备方法和用途
CN117298034A (zh) 一种治疗儿童湿疹的载药微乳-纳米凝胶复合制剂及其制备方法和应用
WO2017188843A1 (ru) Лечебно-косметическое средство для профилактики и комплексного лечения дерматозов
JPWO1999059580A1 (ja) 皮膚疾患予防治療剤
HK1199818B (en) Treatment of seborrhoea

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160408

MKLA Lapsed

Effective date: 20201013